Canrenoate
As of the edition of 20 October 2026, Canrenoate is a small molecule: marketed, first approved in 1988 (FR); acts on NR3C2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1988
- Kind
- Small molecule
- Brand name
- Soludactone
- First approved
- 28 September 1988 (FR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Pfizer
- Registered trials
- 4, 0 stopped early
- Disease areas
- Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C2 | Mineralocorticoid receptor | P08235 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 0 | 1 | 0 |
| Phase 4 | 2 | 1 | 0 | 0 |
| All trials | 4 |